Rethinking Research episode artwork

EPISODE · Jul 7, 2022 · 32 MIN

Rethinking Research

from Health & Veritas

Howie and Harlan discuss a concerning new COVID-19 variant, the discovery casting doubt on a major fish-oil study, and the need for new models of funding research. Links: "New Omicron subvariant Centaurus could be the most immune-evasive yet, expert warns" "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia" "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy" Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions. 

Episode metadata supplied by the publisher feed · Published Jul 7, 2022

Embed this episode

Ready to play

Rethinking Research

0:00 32:28

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Health & Veritas?

This episode is 32 minutes long.

When was this Health & Veritas episode published?

This episode was published on July 7, 2022.

Can I download this Health & Veritas episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!